What Happens When You Stop Taking Ozempic or Mounjaro? New 2026 Research

A new Cleveland Clinic analysis published in March 2026, examining data from nearly 8,000 patients who discontinued semaglutide or tirzepatide, provides the most comprehensive real-world picture yet of what happens after stopping GLP-1 receptor agonist therapy.

The headline finding challenges the widespread narrative that stopping these drugs leads to rapid, dramatic weight regain:

Patients treated for obesity lost an average of 8.4% of body weight before discontinuation and regained an average of just 0.5% one year later.

This is substantially less regain than earlier clinical trial data suggested. The STEP 1 extension trial had shown that patients who stopped semaglutide regained approximately two-thirds of their lost weight within a year, which became the basis for widespread fears that GLP-1 drugs require lifetime use.

The difference between the clinical trial data and the Cleveland Clinic real-world data likely reflects several factors: many patients restart the same medication or switch to an alternative within that year, some patients make lasting lifestyle changes during treatment, and real-world populations differ from the highly selected clinical trial populations.

The gap between clinical trial weight regain data and the Cleveland Clinic real-world findings deserves explanation, because it fundamentally changes how patients should think about GLP-1 therapy.

Restart and switching behavior. In clinical trials, when patients are randomized to stop the drug, they stop entirely. In real-world practice, many patients who discontinue restart the same medication weeks or months later, or switch to an alternative GLP-1 drug. The Cleveland Clinic data captures this natural behavior pattern. This does not mean the drugs are unnecessary — it means the real-world treatment journey is more nuanced than the clinical trial protocol.

Lifestyle modification. Some patients use the period on GLP-1 therapy to establish exercise habits, improve dietary patterns, and address behavioral factors. These changes may persist after drug discontinuation and partially maintain weight loss. GLP-1 drugs reduce appetite and food noise, potentially creating a window for building sustainable habits.

Population differences. Clinical trial participants are carefully selected and monitored. Real-world patients represent a broader population with varying motivations, support systems, and concurrent treatments. The average weight loss of 8.4% in the real-world data is also lower than the 15-20% typically seen in clinical trials, suggesting less aggressive dosing or shorter treatment durations.

Insurance and cost factors. Many patients stop GLP-1 drugs not because they want to but because of cost or insurance coverage changes. These patients are often motivated to maintain their weight loss through other means and may restart when access improves.

Alongside the discontinuation data, March 2026 brought important new head-to-head comparison data between tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy).

NEJM head-to-head trial. A study published in the New England Journal of Medicine provides the first large-scale direct comparison. At 72 weeks, tirzepatide produced significantly greater weight loss than semaglutide, confirming what earlier indirect comparisons suggested.

Real-world confirmation. A Truveta real-world analysis found that at six months, patients on tirzepatide lost an average of 11.15% of body weight compared to 8.83% for semaglutide. At twelve months, the gap widened further: 15.3% for tirzepatide versus 8.3% for semaglutide.

JAMA Internal Medicine data. Rates of clinically meaningful weight loss (10% or more) were 62% with tirzepatide compared to 37% with semaglutide. Rates of 15% or greater weight loss were 42% with tirzepatide versus 18% with semaglutide.

Cardiovascular outcomes may favor semaglutide. The STEER real-world study found that semaglutide demonstrated a 57% greater reduction in major cardiovascular events compared to tirzepatide in patients with established cardiovascular disease. This suggests that the drug with less weight loss may have independent cardiovascular benefits, complicating the simple "more weight loss is better" narrative.

What this means for patients. Tirzepatide appears superior for weight loss, but semaglutide may have advantages for cardiovascular protection. The best choice depends on individual health profiles, insurance coverage, and treatment goals. Both remain highly effective compared to prior weight loss interventions.

If you are considering discontinuing GLP-1 therapy — whether by choice, due to side effects, or because of cost and access — the Cleveland Clinic data offers a more optimistic picture than previously assumed. But planning matters.

Taper gradually. Abrupt discontinuation may increase the likelihood of appetite rebound and weight regain. Work with your prescriber to reduce dosing gradually over several weeks. Most providers recommend stepping down through lower doses before stopping entirely.

Establish habits before stopping. Use the appetite-suppressing effects of GLP-1 therapy as a window to build sustainable eating patterns and exercise routines. Patients who establish regular physical activity and structured eating before discontinuation appear to maintain more of their weight loss.

Monitor closely. Weigh yourself regularly after stopping and have a plan for what to do if weight regain exceeds a threshold you and your provider agree on. Early intervention (restarting medication, intensifying lifestyle measures, or trying an alternative) is more effective than waiting until significant weight is regained.

Consider maintenance dosing. Some providers use lower maintenance doses of GLP-1 drugs rather than full discontinuation. While this has not been studied as rigorously, anecdotal clinical experience suggests that reduced-dose maintenance may help sustain weight loss with fewer side effects and lower cost than full-dose treatment.

Understand the metabolic reality. Obesity involves complex metabolic adaptations that persist after weight loss. Reduced metabolic rate, altered hunger hormones, and increased caloric efficiency are biological responses to weight loss that make regain likely without ongoing intervention. GLP-1 drugs address these mechanisms, and stopping them removes that support. This is a medical reality, not a personal failure.

The GLP-1 landscape continues to evolve rapidly. Several developments on the horizon may change the calculus for patients currently weighing whether to continue or stop therapy.

Oral tirzepatide. A daily pill version of Zepbound (tirzepatide) is expected to reach the market later in 2026. For patients who dislike injections, this could be a reason to continue therapy in a more convenient form.

Retatrutide. This triple-agonist (GIP/GLP-1/glucagon receptor) is in Phase 3 trials with early data showing up to 24% body weight reduction — potentially surpassing both semaglutide and tirzepatide. If approved, it could offer an even more effective option for patients who have plateaued on current drugs.

Amycretin. Novo Nordisk's first-in-class GLP-1/amylin receptor agonist showed up to 24.3% weight loss at 36 weeks in early trials. This single-molecule approach (versus CagriSema's fixed-dose combination) represents the next generation of weight loss pharmacotherapy.

Price reductions. Novo Nordisk announced a 70% price cut for GLP-1 drugs, and compounded versions remain available at $159-259 per month. As prices decrease, the cost barrier to continued therapy diminishes. Insurance coverage is also expanding.

The long-term picture. GLP-1 therapy is increasingly understood as chronic disease management rather than a short-term intervention. This does not mean everyone needs to take these drugs forever, but it does mean that discontinuation should be an informed decision made with realistic expectations about the biological challenges of weight maintenance.